BioSpace News Archive

X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process

Today Mednet, a healthcare technology company, announced a new software release of its eClinical platform, iMednet.

The Biotechnology Innovation Organization (BIO) today released its ninth biennial report, “ The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities ,” which highlights Michigan as a top state for the biosciences. The report studies the state of the U.S. bioscience industry and its associated inno

Antares Pharma, Inc., announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9:40 a.m. Eastern Time.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Linda Bain has joined its Board of Directors.

BridgeBio Pharma, Inc. affiliate ML Bio Solutions announced that the first subject has been dosed in the Phase 1 clinical trial of BBP-418, an orally-administered small molecule therapy being evaluated for the treatment of limb girdle muscular dystrophy type 2i.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced the activation of clinical sites and initiation of enrollment in its Phase II U.S. Food and Drug Administration study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome.

Emerald Health Therapeutics, Inc. announced that, further to its news release on April 29th, Emerald will report its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, June 18, 2020.

Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced that it will present preclinical data on its potent and highly selective STAT3 degraders as well as the first data from its novel IRAKIMiD degraders combining IRAK4 and IMiD substrate degradation.

Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers